key: cord-1055915-tw3j8jke
authors: Verma, Henu Kumar; Merchant, Neha; Bhaskar, L.V.K.S.
title: Reply to the comments on letter to the editor on review article “Current Updates and treatment Strategy of the European and WHO Registered Clinical Trials of Coronavirus Disease 2019”
date: 2021-10-16
journal: Biomed J
DOI: 10.1016/j.bj.2021.10.008
sha: ddbb8e3efede41995fea42a3a4d475f1af752a34
doc_id: 1055915
cord_uid: tw3j8jke

nan

We would like to thank the authors for knowledgeable comments on our study and for clarifying aspects of our methodology in relation to these concerns. We would also like to thank author and his colleagues for their interest in our recently published paper "Current updates on the European and WHO registered clinical trials of coronavirus disease 2019 (COVID-19)" [1], and for taking the time to express their concerns.

One concern was whether the observational studies are to be considered in the clinical J o u r n a l P r e -p r o o f Additionally, the second concern stated in the latter was selecting the Clinical Trials Registry Platform for the study. In this perspective, we would like to mention that the primary goal of our study was to accumulate all currently ongoing clinical trials database results (EU and ClinicalTrials.gov), which has included a majority of the worldwide data in the clinical trials registry platform. However, we selected only the three most extensive clinical trials platform for the analysis.

There are several master protocols available in which multiple treatment options are evaluated concurrently in observational and interventional studies. This design provides flexible features such as dropping treatment options, declaring one or more drug treatments, or adding new treatments to be tested during the course of a trial [2] [3] [4] .

In summary, we would like to thank the author for their concern regarding our article. We believe that our review is beneficial for the scientific community as we summarize the developments in clinical research during the current COVID-19 pandemic. 

hydroquinone alone or in combination with other drugs (n=8), remdesivir (n=6),Tocilizumab, Lopinavir/ ritonavir either single or combined (n=5), Interferon alpha and beta (n=4), Plaquenil (n=4).

Observational and interventional study design types; an overview

Study designs in clinical research

Public availability of results of observational studies evaluating an intervention registered at ClinicalTrials.gov